Search

Author/Creator Clark, Tanya

1. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. (3rd June 2018)

Authors:
Ratnakumaran, Raguprakash; To, Natalie; Gracie, David J.; Selinger, Christian P.; O'Connor, Anthony; Clark, Tanya; Carey, Nicola; Leigh, Katherine; Bourner, Lynsey; Ford, Alexander C.; Hamlin, P. John
Journal:
Scandinavian journal of gastroenterology
Issue:
Volume 53:Number 6(2018)
Page Start:
700
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13). Issue 1 (22nd February 2023)

Authors:
Carbery, Isabel; Burdge, Gemma; Clark, Tanya; Broglio, Giacomo; Greer, Dan; Alakkari, Alaa; Selinger, Christian Philipp
Journal:
BMJ open gastroenterology
Issue:
Volume 10:Issue 1(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease. Issue 12 (December 2017)

Authors:
Selinger, Christian P.; Lenti, Marco V.; Clark, Tanya; Rafferty, Helen; Gracie, David; Ford, Alexander C.; O'Connor, Anthony; Ahmad, Tariq; Hamlin, P. John
Journal:
Inflammatory bowel diseases
Issue:
Volume 23:Issue 12(2017)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗